MSB 12.1% 55.5¢ mesoblast limited

MSB Trading - Aug 2020 on, page-557

  1. 571 Posts.
    lightbulb Created with Sketch. 160
    Is this also not an important part of the report?:


    While remestemcel-L and other MSC-based investigational products have demonstrated apparent immunomodulatory effects in in vitro experiments, the ability of remestemcel-L to reduce inflammation as measured by inflammatory biomarkers in humans receiving the product has not been demonstrated. SR-aGVHD is thought to be an immune-mediated disorder but its etiology is complex and many cell types are likely to be involved in its pathogenesis. Therefore, any efficacy remestemcel-L might have in treating this disease is not sufficient to demonstrate the product’s mechanism of action.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
7 99223 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 44000 4
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 28/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.